fda tirzepatide update today approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA says years-long tirzepatide shortage

Questions to ask your provider Before your first injection, get clear answers to these questions

These drugs are particularly valuable for patients with obesity-related conditions like metabolic syndrome, prediabetes, or as recently approved, obstructive sleep apnea (OSA) the FDA approved tirzepatide in OSA because weight loss led to significant improvement in apnea-hypopnea index and symptom resolutionfda.govfda.gov

Structurally, it is an analogue of the native GIP sequence, modified to include a C20 fatty di-acid moiety

J.SamuelsB

They can schedule unlimited check-ins with their healthcare team to address side effects, adjust dosages, or ask questions all at no extra cost

A similar medication called Wegovy with the same active ingredient, semaglutide, is approved for weight loss and obesity